Shots:
- Luye Pharma has launched Erzofri extended-release injectable suspension in the US to treat adults with schizophrenia & as monotx. or adjunct therapy for adults with schizoaffective disorder
- Erzofri was approved by the US FDA based on a multiple-dose, parallel-group study evaluating its PK profile & relative bioavailability at steady state vs reference product, demonstrating bioequivalence to established paliperidone palmitate LAI on day 8 without requiring the 2nd initiation dose
- Erzofri simplifies treatment with a unique 351mg/2.25mL single-dose initiation & is available in single-use kits across multiple strengths: 39mg/0.25mL, 78mg/0.5mL, 117mg/0.75mL, 156mg/1mL, & 234mg/1.5mL
Ref: Prnewswire | Image: Luye Pharma
Related News:- ABL Bio Licenses Grabody-B Brain Delivery Platform to GSK for ~$2.76B (£2.15B)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
